Heron Therapeutics, Inc.
HRTXHeron Therapeutics, Inc. in brief
Heron Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $57 M on 28 October 2026, which makes it the 20,806th largest listed company in the world and the 3,801st largest in the USA on this site. In the year to December 2025 it had sales of $155 M and a net loss of $20 M. It employs about 302 people and Craig A. Collard is its chief executive. Its largest product and service lines by sales in 2025 were CINVANTI (62%), ZYNRELEF (25%) and APONVIE (7%). Its shares trade under the symbol HRTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Heron Therapeutics, Inc.
Heron Therapeutics is a Developing and Commercializing Pharmaceutical Products company. The headquarters is in USA.
Heron Therapeutics, Inc. timeline
- 1994
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2001
- ✎Renamed Ap Pharma Inc /De/Formerly Advanced Polymer Systems Inc /De/.
- 2014
- ✎Renamed Heron Therapeutics, Inc. /De/Formerly Ap Pharma Inc /De/.
- 2025
- 💰Record revenue of $155 millionFY2025, the highest of the 8 years on record.
Events of Heron Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,518 (Jan 2020) · #1,677 (Jan 2021) · #2,655 (Jan 2022) · #3,185 (Dec 2022) · #3,664 (Jul 2023) · #3,054 (Jan 2024) · #1,740 (Mar 2026) · #3,644 (Aug 2026) · #3,615 (Oct 2026) · #3,805 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.4×
- Price / book
- 4.0×
- Free cash flow yield
- -48.9%
- Net margin (TTM)
- -14.6%
- Operating margin
- -1.6%
- Return on equity
- -150.5%
- Liabilities / assets
- 94.4%
- Revenue growth
- +7.4%
- R&D / revenue
- 8.0%
- Revenue per employee
- $513 K
- Profit per employee
- $-67 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $155M | +7.4% | $-3M | $-20M | -13.0% |
| Dec 2024 | $144M | +13.6% | $-12M | $-14M | -9.4% |
| Dec 2023 | $127M | +18.0% | $-111M | $-111M | -87.0% |
| Dec 2022 | $108M | +24.7% | $-175M | $-182M | -169.1% |
| Dec 2021 | $86M | -2.6% | $-218M | $-221M | -255.6% |
| Dec 2020 | $89M | -39.3% | $-228M | $-227M | -256.4% |
| Dec 2019 | $146M | +88.4% | $-211M | $-205M | -140.3% |
| Dec 2018 | $77M | — | $-184M | $-179M | -230.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-28M | $0M | $-28M | $-0.12 | — |
| Dec 2024 | $-23M | $2M | $-24M | $-0.09 | — |
| Dec 2023 | $-59M | $2M | $-60M | $-0.80 | — |
| Dec 2022 | $-147M | $2M | $-149M | $-1.67 | — |
| Dec 2021 | $-203M | $3M | $-206M | $-2.24 | — |
| Dec 2020 | $-185M | $7M | $-192M | $-2.50 | — |
| Dec 2019 | $-125M | $7M | $-132M | $-2.50 | — |
| Dec 2018 | $-192M | $9M | $-201M | $-2.44 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $35M (-7.7% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 9, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Sep 29, 20268-KCurrent reportMaterial agreement
- Aug 14, 20268-KCurrent reportMaterial agreement
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Jun 25, 20268-KCurrent reportListing notice
- Jun 16, 20268-KCurrent reportShareholder vote
- Jun 2, 20268-KCurrent reportOther events
- May 11, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations
Official filings of Heron Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $155 M
- Operating income
- $-3 M
- Net income
- $-20 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $256 M
- Total liabilities
- $242 M
- Total equity
- $14 M
As of December-2025
Top 100 institutional investors in Heron Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 30,046,828 | 0 (0.00%) | 15.79% | $9 M | Nov 16, 2026 |
| 2 | Clearline Capital LP | 11,026,633 | -357,328 (-3.14%) | 5.80% | $3 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 9,826,332 | -724,418 (-6.87%) | 5.16% | $3 M | Nov 13, 2026 |
| 4 | Tang Capital Management LLC | 8,971,427 | +2,721,427 (+43.54%) | 4.71% | $3 M | Nov 16, 2026 |
| 5 | Velan Capital Investment Management LP | 8,753,290 | 0 (0.00%) | 4.60% | $3 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 7,820,161 | +37,420 (+0.48%) | 4.11% | $2 M | Nov 13, 2026 |
| 7 | Tejara Capital Ltd | 6,492,878 | -17,917 (-0.28%) | 3.41% | $2 M | Nov 9, 2026 |
| 8 | Gsa Capital Partners LLP | 5,473,797 | +4,430,905 (+424.87%) | 2.88% | $2 M | Nov 16, 2026 |
| 9 | Geode Capital Management, LLC | 4,106,017 | -164,963 (-3.86%) | 2.16% | $1 M | Nov 6, 2026 |
| 10 | State Street Corp | 3,203,401 | -25,156 (-0.78%) | 1.68% | $1 M | Nov 12, 2026 |
| 11 | UBS Group AG | 2,105,269 | -891,804 (-29.76%) | 1.11% | $1 M | Nov 10, 2026 |
| 12 | AQR Capital Management LLC | 1,987,205 | +433,348 (+27.89%) | 1.04% | $1 M | Nov 16, 2026 |
| 13 | Renaissance Technologies LLC | 1,569,100 | +62,200 (+4.13%) | 0.82% | $0 M | Nov 12, 2026 |
| 14 | Millennium Management LLC | 1,459,918 | -2,610,183 (-64.13%) | 0.77% | $0 M | Nov 16, 2026 |
| 15 | Caption Management, LLC | 1,383,994 | +383,994 (+38.40%) | 0.73% | $0 M | Nov 16, 2026 |
| 16 | Vanguard Portfolio Management LLC | 1,370,188 | -210,322 (-13.31%) | 0.72% | $0 M | Nov 13, 2026 |
| 17 | Panagora Asset Management Inc | 1,323,436 | +41,640 (+3.25%) | 0.70% | $0 M | Nov 12, 2026 |
| 18 | Goldman Sachs Group Inc | 1,258,587 | -71,167 (-5.35%) | 0.66% | $0 M | Nov 16, 2026 |
| 19 | Vanguard Fiduciary Trust Co | 1,225,732 | -139,387 (-10.21%) | 0.64% | $0 M | Nov 13, 2026 |
| 20 | Northern Trust Corp | 1,206,459 | -17,021 (-1.39%) | 0.63% | $0 M | Nov 16, 2026 |
| 21 | CM Management, LLC | 1,000,000 | 0 (0.00%) | 0.53% | $0 M | Nov 12, 2026 |
| 22 | Invesco Ltd. | 662,160 | +255,492 (+62.83%) | 0.35% | $0 M | Nov 12, 2026 |
| 23 | Squarepoint Ops LLC | 600,287 | +279,110 (+86.90%) | 0.32% | $0 M | Nov 9, 2026 |
| 24 | Congress Park Capital LLC | 551,697 | -1,464,750 (-72.64%) | 0.29% | $0 M | Oct 13, 2026 |
| 25 | Citadel Advisors LLC | 477,208 | New | 0.25% | $0 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nexpoint Asset Management, L.P. | 475,750 | 0 (0.00%) | 0.25% | $0 M | Nov 16, 2026 |
| 27 | Xcelsior Advisor Partners LLC | 466,777 | +61,000 (+15.03%) | 0.25% | $0 M | Nov 13, 2026 |
| 28 | Diadema Partners LP | 458,723 | 0 (0.00%) | 0.24% | $0 M | Nov 16, 2026 |
| 29 | Acadian Asset Management LLC | 394,134 | +241,123 (+157.59%) | 0.21% | $0 M | Nov 9, 2026 |
| 30 | Bank of New York Mellon Corp | 378,609 | -17,229 (-4.35%) | 0.20% | $0 M | Nov 5, 2026 |
| 31 | Marshall Wace, LLP | 357,515 | -1,996,678 (-84.81%) | 0.19% | $0 M | Nov 13, 2026 |
| 32 | Two Sigma Investments, LP | 346,014 | +79,700 (+29.93%) | 0.18% | $0 M | Nov 16, 2026 |
| 33 | Apeiron RIA LLC | 319,123 | -51,456 (-13.89%) | 0.17% | $0 M | Oct 8, 2026 |
| 34 | Barclays PLC | 310,479 | +219,457 (+241.10%) | 0.16% | $0 M | Nov 6, 2026 |
| 35 | Charles Schwab Investment Management Inc | 307,680 | -909,783 (-74.73%) | 0.16% | $0 M | Nov 16, 2026 |
| 36 | Nuveen, LLC | 304,443 | +82,656 (+37.27%) | 0.16% | $0 M | Nov 10, 2026 |
| 37 | Alliancebernstein L.P. | 299,910 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 38 | StoneX Group Inc. | 237,550 | New | 0.12% | $0 M | Nov 3, 2026 |
| 39 | Los Angeles Capital Management LLC | 210,883 | +90,590 (+75.31%) | 0.11% | $0 M | Nov 12, 2026 |
| 40 | Bank Of America Corp /de/ | 180,519 | +72,150 (+66.58%) | 0.09% | $0 M | Nov 16, 2026 |
| 41 | Rhumbline Advisers | 180,444 | -15,093 (-7.72%) | 0.09% | $0 M | Nov 10, 2026 |
| 42 | Quinn Opportunity Partners LLC | 175,344 | 0 (0.00%) | 0.09% | $0 M | Nov 10, 2026 |
| 43 | Qube Research & Technologies Ltd | 172,739 | -848,353 (-83.08%) | 0.09% | $0 M | Nov 13, 2026 |
| 44 | Integrated Wealth Concepts LLC | 169,212 | +9,215 (+5.76%) | 0.09% | $0 M | Nov 17, 2026 |
| 45 | Raymond James Financial Inc | 168,177 | +10,000 (+6.32%) | 0.09% | $0 M | Nov 12, 2026 |
| 46 | BNP Paribas Financial Markets | 158,212 | +135,705 (+602.95%) | 0.08% | $0 M | Nov 12, 2026 |
| 47 | Morgan Stanley | 155,797 | +44,099 (+39.48%) | 0.08% | $0 M | Nov 13, 2026 |
| 48 | JW Asset Management, LLC | 140,863 | -3,610,210 (-96.24%) | 0.07% | $0 M | Nov 6, 2026 |
| 49 | Persistent Asset Partners Ltd | 117,090 | 0 (0.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 50 | Price T Rowe Associates Inc /MD/ | 111,504 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 51 | Glenmede Trust Co NA | 105,326 | New | 0.06% | $0 M | Nov 16, 2026 |
| 52 | HSBC Holdings PLC | 100,000 | +66,619 (+199.57%) | 0.05% | $0 M | Nov 16, 2026 |
| 53 | Biltmore Family Office, LLC | 100,000 | 0 (0.00%) | 0.05% | $0 M | Nov 3, 2026 |
| 54 | Tudor Investment Corp Et Al | 94,864 | New | 0.05% | $0 M | Nov 16, 2026 |
| 55 | SEI Investments Co | 91,036 | +78,351 (+617.67%) | 0.05% | $0 M | Nov 10, 2026 |
| 56 | Richmond Brothers, Inc. | 87,344 | -1,704,975 (-95.13%) | 0.05% | $0 M | Nov 13, 2026 |
| 57 | Searle & Co. | 86,250 | 0 (0.00%) | 0.05% | $0 M | Nov 4, 2026 |
| 58 | Ieq Capital, LLC | 85,899 | -10,713 (-11.09%) | 0.05% | $0 M | Nov 10, 2026 |
| 59 | Deutsche Bank AG\ | 84,183 | -12,117 (-12.58%) | 0.04% | $0 M | Nov 6, 2026 |
| 60 | Vanguard Global Advisers, LLC | 84,053 | +297 (+0.35%) | 0.04% | $0 M | Nov 13, 2026 |
| 61 | D. E. Shaw & Co., Inc. | 81,666 | -38,769 (-32.19%) | 0.04% | $0 M | Nov 16, 2026 |
| 62 | Susquehanna International Group, LLP | 81,444 | -55,623 (-40.58%) | 0.04% | $0 M | Nov 16, 2026 |
| 63 | Russell Investments Group, Ltd. | 81,246 | 0 (0.00%) | 0.04% | $0 M | Nov 6, 2026 |
| 64 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 77,457 | +3,872 (+5.26%) | 0.04% | $0 M | Nov 16, 2026 |
| 65 | Mercer Global Advisors Inc /adv | 73,857 | +5,566 (+8.15%) | 0.04% | $0 M | Nov 16, 2026 |
| 66 | Jpmorgan Chase & Co | 71,925 | -3,740 (-4.94%) | 0.04% | $0 M | Nov 12, 2026 |
| 67 | Cerity Partners LLC | 65,795 | +5,454 (+9.04%) | 0.03% | $0 M | Nov 13, 2026 |
| 68 | R Squared Ltd | 62,671 | +15,963 (+34.18%) | 0.03% | $0 M | Nov 6, 2026 |
| 69 | LPL Financial LLC | 62,328 | +1,216 (+1.99%) | 0.03% | $0 M | Nov 6, 2026 |
| 70 | Commonwealth Equity Services, LLC | 59,176 | 0 (0.00%) | 0.03% | $0 M | Nov 2, 2026 |
| 71 | Creative Planning | 57,128 | +21,266 (+59.30%) | 0.03% | $0 M | Nov 2, 2026 |
| 72 | Redwood Family Wealth LLC | 55,972 | -49,500 (-46.93%) | 0.03% | $0 M | Oct 20, 2026 |
| 73 | Captrust Financial Advisors | 52,950 | +1,403 (+2.72%) | 0.03% | $0 M | Nov 12, 2026 |
| 74 | Wells Fargo & Company/mn | 51,379 | -101,544 (-66.40%) | 0.03% | $0 M | Nov 16, 2026 |
| 75 | Vanguard Personalized Indexing Management, LLC | 47,209 | +19,933 (+73.08%) | 0.02% | $0 M | Nov 16, 2026 |
| 76 | DLK Investment Management, LLC | 44,710 | +26,820 (+149.92%) | 0.02% | $0 M | Oct 9, 2026 |
| 77 | Mariner, LLC | 41,746 | -14,226 (-25.42%) | 0.02% | $0 M | Nov 12, 2026 |
| 78 | Public Employees Retirement System Of Ohio | 41,640 | New | 0.02% | $0 M | Nov 16, 2026 |
| 79 | HORAN Wealth, LLC | 41,590 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 80 | Centiva Capital, LP | 40,083 | -5,424 (-11.92%) | 0.02% | $0 M | Nov 13, 2026 |
| 81 | New Harbor Financial Group, LLC | 39,120 | New | 0.02% | $0 M | Oct 22, 2026 |
| 82 | Police & Firemen's Retirement System of New Jersey | 38,352 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 83 | Prospera Financial Services Inc | 36,085 | -4,480 (-11.04%) | 0.02% | $0 M | Nov 4, 2026 |
| 84 | King Wealth Management Group | 34,799 | +2,000 (+6.10%) | 0.02% | $0 M | Nov 9, 2026 |
| 85 | DDFG, Inc | 32,903 | 0 (0.00%) | 0.02% | $0 M | Oct 15, 2026 |
| 86 | Tower Research Capital LLC (TRC) | 32,609 | -2,958 (-8.32%) | 0.02% | $0 M | Nov 16, 2026 |
| 87 | Group One Trading LLC | 32,110 | -5,837 (-15.38%) | 0.02% | $0 M | Nov 10, 2026 |
| 88 | Concurrent Investment Advisors, LLC | 31,923 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 89 | Pallas Capital Advisors LLC | 31,133 | +5,434 (+21.14%) | 0.02% | $0 M | Nov 12, 2026 |
| 90 | Horizon Investments, LLC | 30,000 | New | 0.02% | $0 M | Nov 13, 2026 |
| 91 | Wealth Enhancement Advisory Services, LLC | 29,067 | -3,330 (-10.28%) | 0.02% | $0 M | Oct 13, 2026 |
| 92 | CoreCap Advisors, LLC | 28,409 | 0 (0.00%) | 0.01% | $0 M | Oct 8, 2026 |
| 93 | Diversified Trust Co | 26,492 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 94 | Royal Bank Of Canada | 26,154 | +20,694 (+379.01%) | 0.01% | $0 M | Nov 16, 2026 |
| 95 | ACT Advisors, LLC. | 25,581 | New | 0.01% | $0 M | Oct 15, 2026 |
| 96 | J.W. Cole Advisors, Inc. | 25,000 | +10,000 (+66.67%) | 0.01% | $0 M | Nov 5, 2026 |
| 97 | Parkway Wealth Management Group, LLC | 25,000 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 98 | Prudential Financial Inc | 23,495 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | &partners | 22,927 | -705 (-2.98%) | 0.01% | $0 M | Nov 16, 2026 |
| 100 | HighTower Advisors, LLC | 22,263 | -2,354 (-9.56%) | 0.01% | $0 M | Nov 10, 2026 |
Mutual funds holding Heron Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 5.47 M | $2 M | 4.2% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.68 M | $2 M | 2.9% | <0.01% | −4.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 2.06 M | $1 M | 1.6% | <0.01% | +1.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.63 M | $1 M | 1.3% | <0.01% | +7.9% | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 869,904 | $1 M | 0.67% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 783,992 | $1 M | 0.61% | <0.01% | +3.3% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 1.36 M | $1 M | 1.1% | <0.01% | +786% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 666,160 | $1 M | 0.52% | <0.01% | −22% | May 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 415,508 | $0 M | 0.32% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 318,641 | $0 M | 0.25% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 273,188 | $0 M | 0.21% | <0.01% | +3.9% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 537,335 | $0 M | 0.42% | 0.02% | +39% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 510,428 | $0 M | 0.40% | <0.01% | −56% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 413,595 | $0 M | 0.32% | <0.01% | +22% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 265,032 | $0 M | 0.21% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 241,129 | $0 M | 0.19% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 Highland Global Allocation FundHighland Global Allocation Fund | 232,800 | $0 M | 0.18% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 198,783 | $0 M | 0.15% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 198,800 | $0 M | 0.15% | <0.01% | −9.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 103,673 | $0 M | 0.08% | <0.01% | +4.8% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 88,334 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 175,959 | $0 M | 0.14% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 83,361 | $0 M | 0.06% | <0.01% | +1.2% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 162,509 | $0 M | 0.13% | <0.01% | +94% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 157,240 | $0 M | 0.12% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 137,543 | $0 M | 0.11% | <0.01% | +901% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 129,323 | $0 M | 0.10% | <0.01% | −33% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 128,160 | $0 M | 0.10% | <0.01% | +65% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 62,537 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 118,392 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 115,110 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 88,576 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 45,455 | $0 M | 0.04% | 0.02% | −16% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 76,332 | $0 M | 0.06% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 40,788 | $0 M | 0.03% | 0.02% | −16% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 66,714 | $0 M | 0.05% | <0.01% | +8.6% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 64,721 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 49,610 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 48,817 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 48,604 | $0 M | 0.04% | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 37,137 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 20,900 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 40,509 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 33,418 | $0 M | 0.03% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 18,407 | $0 M | 0.01% | <0.01% | +2.7% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 36,443 | $0 M | 0.03% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 34,050 | $0 M | 0.03% | <0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 28,777 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 28,685 | $0 M | 0.02% | <0.01% | −83% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 28,254 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 12,513 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 12,300 | $0 M | <0.01% | <0.01% | −51% | May 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 20,897 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 23,391 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 20,226 | $0 M | 0.02% | <0.01% | −4.7% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 17,391 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 20,025 | $0 M | 0.02% | <0.01% | +1023% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 19,769 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 19,468 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 17,474 | $0 M | 0.01% | <0.01% | −22% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 15,618 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 7,231 | $0 M | <0.01% | <0.01% | +8.6% | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 13,394 | $0 M | 0.01% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 11,114 | $0 M | <0.01% | <0.01% | +1134% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 12,671 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 11,993 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 5,714 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 5,655 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 10,661 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 10,051 | $0 M | <0.01% | <0.01% | −94% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 4,679 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 4,190 | $0 M | <0.01% | <0.01% | −5.2% | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 6,399 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 5,088 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 5,641 | $0 M | <0.01% | <0.01% | −56% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 4,710 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 4,372 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 3,854 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 3,827 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 3,307 | $0 M | <0.01% | <0.01% | −1.4% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 960 | $0 M | <0.01% | <0.01% | −80% | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 1,020 | $0 M | <0.01% | <0.01% | +8.9% | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 800 | $0 M | <0.01% | <0.01% | −64% | Jun 30, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 268 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 84 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Heron Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark Earl HensleyChief Operating Officer | Option exercise | +31,250 | — | — | 210,572 | Form 4 |
| filed | Mark Earl HensleyChief Operating Officer | Shares withheld for tax | -8,889 | $0.290 | $3 K | 201,683 | Form 4 |
| filed | Ira DuarteEVP, Chief Financial Officer | Option exercise | +11,695 | — | — | 306,051 | Form 4 |
| filed | Craig A. CollardChief Executive Officer, Director | Option exercise | +34,788 | — | — | 939,557 | Form 4 |
| filed | William P. ForbesEVP, Chief Development Officer | Option exercise | +11,695 | — | — | 264,061 | Form 4 |
| filed | William P. ForbesEVP, Chief Development Officer | Shares withheld for tax | -3,327 | $0.280 | $932 | 260,734 | Form 4 |
| filed | Craig A. CollardChief Executive Officer, Director | Shares withheld for tax | -8,471 | $0.280 | $2 K | 931,086 | Form 4 |
| filed | Ira DuarteEVP, Chief Financial Officer | Shares withheld for tax | -3,327 | $0.280 | $932 | 302,724 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Heron Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 224,110 shares at $0.30
- : 34,726 shares at $0.34
- : 12,912 shares at $0.35
- : 712 shares at $0.38
- : 63,562 shares at $0.36
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Heron Therapeutics, Inc. scorecard#
Passes 8 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median4.0×Price to book 4.0× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-48.9%Free cash flow is -48.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year7.4%Revenue up 7.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years12.9%12.9% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median12.9%12.9% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.12 vs -0.09Diluted EPS -0.12 in fiscal 2025 against -0.09 the year before (report's currency).
- ✓Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$227 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability2 of 4
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-1.6%-1.6% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-1.6%-1.6% in fiscal 2025 against -162.2% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.48 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-9.23Z-score -9.23 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year9.3%Diluted shares up 9.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Heron Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -1.6% | -60.5% | |
| Net margin | -13.0% | -68.9% | |
| Revenue growth, 3 years a year | 12.9% | 12.9% | |
| Revenue growth | 7.4% | 15.8% | |
| Free cash flow margin | -18.0% | -61.5% |
2of 8on the Piotroski tests of financial strength
- Net loss of $20 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$28 million.
- The share count rose 9.3% in the year.
- Revenue has grown 4 years in a row.
Heron Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 155+7.4%100% | 144+13.6%100% | 127+18.0%100% | 108+24.7%100% | 86−2.6%100% | 89−39.3%100% | 146+88.4%100% | 77+152%100% | 31+2306%100% | 1.3—100% | |
| Cost of revenue | 41+7.0%26.7% | 39−40.6%26.8% | 65+18.6%51.2% | 55+19.2%51.0% | 46+27.2%53.3% | 36−41.3%40.8% | 62+124%42.2% | 28+500%35.5% | 4.6+13009%14.9% | 0.0—2.7% | |
| Gross profit | 114+7.5%73.3% | 106+70.6%73.2% | 62+17.3%48.8% | 53—49.0% | — | — | — | — | — | — | |
| Research and development | 12−25.5%8.0% | 17−57.4%11.6% | 39r56−52.7%30.8% | 83r108−36.8%76.8% | 131−25.0%152% | 175+4.3%197% | 167+19.5%115% | 140+1.0%181% | 139+34.4%450% | 103—8063% | |
| Selling and marketing | 49+4.2%31.7% | 47−30.4%32.6% | 68−18.0%53.2% | 83−5.4%76.6% | 87+36.5%101% | 64−28.9%72.0% | 90+38.9%61.5% | 65+14.1%83.4% | 57+18.7%184% | 48—3727% | |
| General and administrative | 55+2.3%35.3% | 53−18.8%37.0% | 66r49+5.7%51.8% | 62r37+55.0%57.8% | 40−4.9%46.5% | 42+11.4%47.6% | 38+29.5%26.0% | 29+14.5%37.8% | 26+19.6%83.1% | 21—1671% | |
| Operating expenses | — | — | — | — | — | — | — | 261+16.0%337% | 225+30.9%732% | 172—13463% | |
| Total costs and expenses | 116−0.9%74.9% | 117−32.1%81.2% | 173−24.1%136% | 227r282−25.2%211% | 304−4.0%352% | 317−11.2%357% | 357+36.4%244% | 261+16.0%337% | 225—732% | — | |
| Operating income | −2.5—−1.6% | −12—−8.0% | −111—−87.1% | −175—−162% | −218—−252% | −228—−257% | −211—−144% | −184—−237% | −195—−632% | −171—−13363% | |
| Interest and finance income | 1.9−45.1%1.3% | 3.6+5.5%2.5% | 3.4+105%2.6% | 1.6+278%1.5% | 0.4−88.1%0.5% | 3.6−50.0%4.1% | 7.3+21.7%5.0% | 6.0+469%7.7% | 1.0+136%3.4% | 0.4—34.8% | |
| Interest expense and finance costs | 9.6+59.2%6.2% | 6.0+55.9%4.2% | 3.9+56.3%3.0% | 2.5+2.7%2.3% | 2.4+26.8%2.8% | 1.9+29.1%2.1% | 1.5−44.9%1.0% | 2.7−32.1%3.4% | 3.9+47.8%12.8% | 2.7—208% | |
| Other non-operating income (expense) | −18—−11.4% | −2.1−3764%−1.4% | 0.1—0.0% | −7.4—−6.8% | −2.9−423%−3.3% | 0.9−85.1%1.0% | 5.9+16.6%4.1% | 5.1—6.6% | −2.9—−9.5% | −2.2—−174% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −20—−13.0% | −14—−9.4% | −111—−87.0% | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −20—−13.0% | −14—−9.4% | −111—−87.0% | −182—−169% | −221—−256% | −227—−256% | −205—−140% | −179—−231% | −197—−642% | −173—−13537% | |
| Earnings per share, basic | -0.12—— | -0.09—— | -0.80—— | -1.67—— | -2.24—— | -2.50—— | -2.50—— | -2.44—— | -3.65—— | -4.56—— | |
| Earnings per share, diluted | -0.12—— | -0.09—— | -0.80—— | -1.67—— | -2.24—— | -2.50—— | -2.50—— | -2.44—— | -3.65—— | -4.56—— | |
| Shares, weighted average (basic) | 167+9.4%— | 152+10.4%— | 138+26.9%— | 109r0.1+110467%— | 0.1—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 167+9.4%— | 152+10.4%— | 138+26.9%— | 109r0.1+110467%— | 0.1r98−99.9%— | 91+11.0%— | 82+11.7%— | 73+35.4%— | 54+42.5%— | 38—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 29+11.0%11.2% | 26−10.0%11.1% | 29+86.7%12.9% | 15−83.0%6.1% | 91−13.9%29.6% | 105+46.2%29.7% | 72+126%14.0% | 32−78.0%6.9% | 145+978%61.7% | 13—19.9% | |
| Short-term investments | 18−46.3%7.0% | 33−35.3%14.4% | 52−25.6%23.2% | 69+3.7%27.7% | 67−35.1%21.9% | 103−67.6%29.2% | 319+6.2%62.2% | 301—65.0% | — | — | |
| Receivables | 90+13.6%35.0% | 79+31.2%33.8% | 60+15.5%27.0% | 52+46.6%20.7% | 35−15.2%11.6% | 42+4.9%11.8% | 40−38.3%7.8% | 65+54.4%14.0% | 42+2036%17.9% | 2.0—2.9% | |
| Inventory | 93+74.5%36.2% | 53+26.2%22.8% | 42−22.8%18.9% | 55+12.8%21.7% | 48+15.5%15.8% | 42+67.8%11.9% | 25−36.0%4.9% | 39+286%8.4% | 10+89.3%4.3% | 5.3—7.9% | |
| Other current assets | 9.1−48.5%3.6% | 18+189%7.6% | 6.1−56.2%2.7% | 14+7.7%5.6% | 13−40.9%4.2% | 22−5.6%6.2% | 23+108%4.5% | 11+202%2.4% | 3.7−0.1%1.6% | 3.7—5.5% | |
| Current assets | 238+13.9%93.0% | 209+10.7%89.6% | 189−8.1%84.8% | 205−19.3%81.9% | 254−19.0%83.2% | 314−34.4%88.9% | 479+7.1%93.4% | 447+96.1%96.8% | 228+267%97.3% | 62—92.1% | |
| Property, plant and equipment | 12−16.6%4.8% | 15−26.3%6.4% | 20−9.0%9.1% | 22−6.6%8.8% | 24+4.4%7.8% | 23+15.9%6.4% | 20+33.7%3.8% | 15+145%3.2% | 6.0+17.8%2.6% | 5.1—7.5% | |
| Right-of-use (leased) assets | 0−100%0.0% | 2.8−48.7%1.2% | 5.4−28.9%2.4% | 7.6−22.2%3.0% | 9.8−39.6%3.2% | 16+18.3%4.6% | 14—2.7% | — | — | — | |
| Total assets | 256+9.7%100% | 233+4.8%100% | 223−11.3%100% | 251−17.9%100% | 306−13.5%100% | 354−31.1%100% | 513+10.9%100% | 462+97.3%100% | 234+247%100% | 67—100% | |
| Accounts payable | 9.0−23.2%3.5% | 12+261%5.0% | 3.2+0.5%1.5% | 3.2−15.2%1.3% | 3.8+624%1.2% | 0.5−81.0%0.1% | 2.8−83.6%0.5% | 17−10.2%3.6% | 19+175%8.0% | 6.8—10.1% | |
| Current liabilities | 96+5.1%37.6% | 91+14.8%39.2% | 80−3.2%35.8% | 82+15.9%32.8% | 71−30.7%23.2% | 103+6.0%29.0% | 97+5.1%18.9% | 92−10.8%19.9% | 103+166%44.0% | 39—57.4% | |
| Lease liabilities (non-current) | 0—0.0% | — | 2.8−49.1%1.3% | 5.5−31.2%2.2% | 8.0−45.1%2.6% | 15+18.9%4.1% | 12—2.4% | — | — | — | |
| Total liabilities | 242−9.5%94.4% | 267+4.0%114% | 256+8.0%115% | 237+4.1%94.6% | 228+94.9%74.6% | 117+7.5%33.1% | 109+18.4%21.2% | 92−10.8%19.9% | 103+16.3%44.0% | 89—131% | |
| Retained earnings | −1,940—−758% | −1,920—−823% | −1,906—−857% | −1,795—−715% | −1,613—−528% | −1,393—−394% | −1,165—−227% | −961—−208% | −783—−334% | −586—−868% | |
| Shareholders' equity | 14—5.6% | −34—−14.4% | −34−350%−15.3% | 14−82.5%5.4% | 78−67.2%25.4% | 236−41.4%66.9% | 404+9.1%78.8% | 370+182%80.1% | 131—56.0% | −21—−31.5% | |
| Total liabilities and equity | 256+9.7%100% | 233+4.8%100% | 223−11.3%100% | 251−17.9%100% | 306−13.5%100% | 354−31.1%100% | 513+10.9%100% | 462+97.3%100% | 234+247%100% | 67—100% | |
| Shares outstanding | 188+23.8%— | 152+1.2%— | 150+26.1%— | 119r119+16.8%— | 102+11.7%— | 91+1.1%— | 90+15.5%— | 78+21.0%— | 65r0.1+164070%— | 0.0r39—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 2.3−7.1%1.5% | 2.5−14.0%1.7% | 2.9+0.3%2.3% | 2.9−4.4%2.7% | 3.0+6.1%3.5% | 2.8+39.3%3.2% | 2.0+35.1%1.4% | 1.5−1.2%2.0% | 1.5+39.3%5.0% | 1.1—85.9% | |
| Share-based compensation | 10−20.2%6.7% | 13−60.5%9.0% | 33−23.6%25.9% | 43−8.3%39.9% | 47−6.7%54.3% | 50−2.3%56.7% | 51+54.1%35.2% | 33+9.3%43.1% | 31+17.7%99.3% | 26—2029% | |
| Cash from operating activities | −28—−17.8% | −23—−15.6% | −59—−46.3% | −147—−136% | −203—−236% | −185—−209% | −125—−85.3% | −192—−248% | −170—−554% | −134—−10485% | |
| Capital expenditure | −0.3—−0.2% | −1.7—−1.2% | −1.5—−1.2% | −1.8—−1.7% | −3.0—−3.5% | −6.8—−7.7% | −7.2—−4.9% | −9.2—−11.8% | −2.6—−8.3% | −3.1—−245% | |
| Cash from investing activities | 16−14.5%10.3% | 19+4.0%13.0% | 18—14.2% | −3.3−110%−3.1% | 33−84.3%37.9% | 209—236% | −22—−14.9% | −279−3700%−360% | 7.7−48.0%25.2% | 15—1163% | |
| Debt repaid | — | — | — | — | — | — | — | −25—−32.3% | −25—−81.3% | — | |
| Shares issued | 18—11.8% | — | 30−60.4%23.4% | 75—69.8% | — | — | 162−55.3%111% | 363+18.6%469% | 306—995% | — | |
| Cash from financing activities | 14+1435%9.3% | 0.9−98.3%0.7% | 54−27.9%42.6% | 75−51.9%69.7% | 156+1614%181% | 9.1−95.1%10.3% | 186−47.9%128% | 358+21.7%462% | 294+411%955% | 57—4492% | |
| Change in cash | 2.8—1.8% | −2.9−122%−2.0% | 13—10.5% | −75—−69.8% | −15−144%−16.9% | 33−17.0%37.5% | 40—27.4% | −113−186%−146% | 131—426% | −62—−4829% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 148−4.4%100% | 35−7.8%100% | 38+1.3%100% | 35−10.8%100% | 41*−0.5%100% | 38+16.5%100% | 37+3.3%100% | 39+12.2%100% | 41*+19.1%100% | 33—100% | 36—100% | 35—100% | 34*—100% | |
| Cost of revenue | 42+4.5%28.5% | 9.0−24.8%25.4% | 12+17.4%30.7% | 11+25.8%30.6% | 11*+8.7%27.4% | 12+26.0%31.2% | 9.9−6.3%26.5% | 8.5+0.2%21.7% | 10*+3.5%25.1% | 9.5—28.8% | 11—29.2% | 8.4—24.4% | 9.9*—28.9% | |
| Gross profit | 106−7.6%71.5% | 26−0.0%74.6% | 26−4.6%69.3% | 24−20.9%69.4% | 29*−3.5%72.6% | 26+12.6%68.8% | 27+7.2%73.5% | 30+16.1%78.3% | 31*+25.5%74.9% | 23—71.2% | 26—70.8% | 26—75.6% | 24*—71.1% | |
| Research and development | 12+0.6%8.1% | 3.1−10.7%8.8% | 2.7−7.9%7.2% | 2.4+4.7%6.9% | 3.7*+17.9%9.2% | 3.5−22.3%9.1% | 2.9−33.8%7.9% | 2.3−50.5%5.9% | 3.2*−59.3%7.8% | 4.5—13.6% | 4.4—12.3% | 4.6—13.3% | 7.8r11*—22.8% | |
| Selling and marketing | 53+11.1%35.9% | 13−3.3%35.5% | 14+22.3%37.6% | 14+16.2%41.2% | 12*+10.6%30.1% | 13+18.0%33.9% | 12−15.0%31.1% | 12+7.6%31.6% | 11*−10.3%27.1% | 11—33.4% | 14—37.8% | 11—33.0% | 12*—36.0% | |
| General and administrative | 49−7.7%33.2% | 12−11.7%35.0% | 11−22.1%29.9% | 12−4.4%35.0% | 13*+10.8%33.1% | 14+13.0%36.6% | 14+4.1%38.9% | 13−15.2%32.7% | 12*−15.9%29.8% | 12—37.7% | 14—38.6% | 15—43.2% | 14r11*—42.2% | |
| Total costs and expenses | 114+1.2%77.2% | 28−8.0%79.3% | 28−2.9%74.7% | 29+5.7%83.1% | 29*+11.6%72.5% | 30+9.3%79.5% | 29−9.3%77.9% | 27−12.0%70.2% | 26*−23.7%64.7% | 28—84.8% | 32—88.7% | 31—89.5% | 35*—101% | |
| Operating income | −8.4−628%−5.7% | −1.7—−4.7% | −2.0—−5.4% | −4.8−251%−13.7% | 0.0*−99.1%0.1% | −4.1—−10.7% | −1.6—−4.4% | 3.2—8.1% | 4.2*—10.2% | −4.5—−13.6% | −6.4—−17.9% | −4.8—−13.8% | −10*—−29.9% | |
| Other non-operating income (expense) | −5.5—−3.7% | −3.3—−9.5% | −3.4—−9.1% | −3.3—−9.6% | 4.7*+137%11.5% | −2.1—−5.4% | −0.7—−2.0% | −0.5−132%−1.3% | 2.0*—4.8% | −0.4—−1.2% | −2.8—−7.7% | 1.6—4.7% | 0*—0.0% | |
| Net income including minority interests | −22—−14.5% | −5.0*—−14.2% | −5.5*—−14.6% | −8.1−408%−23.4% | −3.0*−181%−7.3% | −17*—−45.8% | −2.4*—−6.4% | 2.6—6.8% | 3.7*—9.0% | — | — | — | — | |
| Net income attributable to shareholders | −22—−14.5% | −5.0—−14.2% | −5.5—−14.6% | −8.1−408%−23.4% | −3.0*−181%−7.3% | −17—−45.8% | −2.4—−6.4% | 2.6—6.8% | 3.7*—9.0% | −4.8—−14.8% | −9.2—−25.6% | −3.2—−9.1% | −11*—−31.3% | |
| Earnings per share, basic | — | -0.03—— | -0.03—— | -0.04−300%— | — | -0.10—— | -0.02—— | 0.02—— | — | -0.03—— | -0.06—— | -0.02—— | — | |
| Earnings per share, diluted | — | -0.03—— | -0.03—— | -0.04−500%— | — | -0.10—— | -0.02—— | 0.01—— | — | -0.03—— | -0.06—— | -0.02—— | — | |
| Shares, weighted average (basic) | 191+12.1%— | 191+12.1%— | 190+23.6%— | 190+23.6%— | — | 170+11.5%— | 154+1.1%— | 153+1.5%— | — | 153—— | 152—— | 151—— | — | |
| Shares, weighted average (diluted) | 191+12.1%— | 191+12.1%— | 190+23.6%— | 190−3.7%— | — | 170+11.5%— | 154+1.1%— | 197+30.2%— | — | 153—— | 152—— | 151—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 12—5.0% | 12−73.1%5.0% | 21+25.5%8.2% | 26+35.5%10.6% | 29+11.0%11.2% | 43+67.3%17.3% | 17−10.2%7.1% | 19−5.8%8.2% | 26−10.0%11.1% | 26—11.7% | 18—8.4% | 20—9.4% | 29—12.9% | |
| Short-term investments | 12—5.1% | 12−4.5%5.1% | 22−9.0%8.7% | 19−40.6%7.6% | 18−46.3%7.0% | 12−72.5%5.0% | 24−50.7%10.4% | 31−38.5%13.3% | 33−35.3%14.4% | 45—20.5% | 49—22.4% | 51—23.4% | 52—23.2% | |
| Receivables | 87—37.6% | 87+7.0%37.6% | 90+12.1%35.5% | 84+6.3%34.0% | 90+13.6%35.0% | 81+20.9%32.6% | 80+8.4%34.4% | 79+20.5%33.4% | 79+31.2%33.8% | 67—30.4% | 74—33.8% | 65—30.0% | 60—27.0% | |
| Inventory | 91—39.6% | 91+30.4%39.6% | 91+24.1%35.9% | 93+62.5%37.6% | 93+74.5%36.2% | 70+52.4%28.1% | 73+70.2%31.4% | 57+34.0%24.1% | 53+26.2%22.8% | 46—20.8% | 43—19.7% | 42—19.5% | 42—18.9% | |
| Other current assets | 7.6—3.3% | 7.6−66.6%3.3% | 7.0−59.6%2.8% | 8.0−69.9%3.2% | 9.1−48.5%3.6% | 23+102%9.2% | 17+140%7.5% | 26+302%11.2% | 18+189%7.6% | 11—5.1% | 7.2—3.3% | 6.6—3.0% | 6.1—2.7% | |
| Current assets | 209—90.7% | 209−8.8%90.7% | 230+9.0%91.1% | 229+7.6%93.0% | 238+13.9%93.0% | 229+17.5%92.1% | 211+10.3%90.9% | 213+14.5%90.3% | 209+10.7%89.6% | 195—88.4% | 191—87.6% | 186—85.3% | 189—84.8% | |
| Property, plant and equipment | 11—4.8% | 11−14.5%4.8% | 12−13.7%4.7% | 12−17.3%4.9% | 12−16.6%4.8% | 13−15.9%5.2% | 14−13.9%5.9% | 15−24.7%6.2% | 15−26.3%6.4% | 15—7.0% | 16—7.3% | 19—8.9% | 20—9.1% | |
| Right-of-use (leased) assets | 5.4—2.4% | 5.4+669%2.4% | 5.6+299%2.2% | — | 0−100%0.0% | 0.7−79.6%0.3% | 1.4−66.1%0.6% | 2.1−56.4%0.9% | 2.8−48.7%1.2% | 3.5—1.6% | 4.1—1.9% | 4.8—2.2% | 5.4—2.4% | |
| Total assets | 230—100% | 230−7.4%100% | 252+8.7%100% | 246+4.4%100% | 256+9.7%100% | 249+12.8%100% | 232+6.4%100% | 236+8.2%100% | 233+4.8%100% | 221—100% | 218—100% | 218—100% | 223—100% | |
| Accounts payable | 8.4—3.6% | 8.4−30.3%3.6% | 12−3.3%4.6% | 9.0−27.3%3.6% | 9.0−23.2%3.5% | 12+18.0%4.8% | 12+17.7%5.2% | 12+1373%5.2% | 12+261%5.0% | 10—4.6% | 10—4.7% | 0.8—0.4% | 3.2—1.5% | |
| Current liabilities | 90—39.0% | 90+0.2%39.0% | 92−64.4%36.5% | 91+2.2%36.8% | 96+5.1%37.6% | 90+4.9%36.0% | 259+222%111% | 89+17.5%37.6% | 91+14.8%39.2% | 86—38.7% | 80—36.8% | 75—34.6% | 80—35.8% | |
| Lease liabilities (non-current) | 5.4—2.3% | 5.4—2.3% | 5.5—2.2% | — | 0—0.0% | — | — | — | — | 0.5—0.2% | 1.3—0.6% | 2.0—0.9% | 2.8—1.3% | |
| Total liabilities | 226—97.9% | 226−3.6%97.9% | 245−5.4%97.3% | 237−10.3%96.3% | 242−9.5%94.4% | 234−10.2%94.0% | 259+1.3%112% | 264+5.0%112% | 267+4.0%114% | 261—118% | 256—117% | 252—115% | 256—115% | |
| Retained earnings | −1,958—−850% | −1,958—−850% | −1,953—−774% | −1,948—−791% | −1,940—−758% | −1,937—−778% | −1,919—−827% | −1,917—−813% | −1,920—−823% | −1,923—−871% | −1,918—−879% | −1,909—−876% | −1,906—−857% | |
| Shareholders' equity | 4.9—2.1% | 4.9−67.0%2.1% | 6.9—2.7% | 9.1—3.7% | 14—5.6% | 15—6.0% | −27—−11.7% | −28—−12.1% | −34—−14.4% | −40—−18.1% | −38—−17.4% | −34—−15.5% | −34—−15.3% | |
| Total liabilities and equity | 230—100% | 230−7.4%100% | 252+8.7%100% | 246+4.4%100% | 256+9.7%100% | 249+12.8%100% | 232+6.4%100% | 236+8.2%100% | 233+4.8%100% | 221—100% | 218—100% | 218—100% | 223—100% | |
| Shares outstanding | — | — | — | — | 188+23.8%— | — | — | — | 152+1.2%— | — | — | — | 150—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.9−19.0%1.3% | 0.4*−36.4%1.1% | 0.5*−26.0%1.2% | 0.5−4.0%1.5% | 0.5*−7.6%1.3% | 0.6*+5.9%1.6% | 0.6*−4.7%1.6% | 0.6−20.0%1.4% | 0.6*−18.7%1.4% | 0.6*—1.8% | 0.6*—1.8% | 0.7—2.0% | 0.7*—2.1% | |
| Share-based compensation | 11+9.2%7.7% | 3.1+8.1%8.7% | 3.2+13.6%8.4% | 3.0+18.5%8.6% | 2.2*−5.1%5.4% | 2.9+4.8%7.5% | 2.8−38.8%7.5% | 2.5−25.6%6.5% | 2.3*−46.9%5.6% | 2.7—8.3% | 4.6—12.7% | 3.4—9.7% | 4.3*—12.6% | |
| Cash from operating activities | −14—−9.3% | −0.8*−160%−2.3% | −2.2*—−5.9% | −1.5—−4.4% | −9.2*—−22.6% | 1.3*−60.5%3.5% | −11*—−29.2% | −8.9—−22.8% | −12*−580%−28.9% | 3.4*—10.3% | −4.6*—−12.8% | −9.5—−27.4% | 2.5*—7.2% | |
| Capital expenditure | −0.6—−0.4% | −0.1*—−0.3% | −0.1*—−0.4% | −0.4—−1.1% | 0*—0.0% | 0*—0.0% | −0.2*—−0.6% | −0.1—−0.3% | −0.6*—−1.6% | −0.4*—−1.3% | — | — | −0.3*—−0.7% | |
| Cash from investing activities | 0.4−98.7%0.3% | 10*−14.9%28.6% | −3.3*−145%−8.7% | −0.9−141%−2.7% | −5.5*−148%−13.4% | 12*+199%31.0% | 7.3*+258%19.7% | 2.3+77.9%5.8% | 11*—28.0% | 4.0*—12.1% | 2.0*—5.7% | 1.3—3.7% | −8.8*—−25.8% | |
| Shares issued | — | — | — | — | −1.5*—−3.8% | — | — | — | — | — | — | — | — | |
| Cash from financing activities | −18−224%−12.3% | −18*−238%−52.3% | 0.1*−89.5%0.2% | −0.1−180%−0.1% | 0.2*−48.2%0.5% | 13*+95350%35.0% | 0.8*+58.7%2.1% | 0.1+482%0.2% | 0.4*+113%1.0% | 0.0*—0.0% | 0.5*—1.4% | 0.0—0.0% | 0.2*—0.6% | |
| Change in cash | −31−282%−21.2% | −9.1*−134%−25.9% | −5.4*—−14.3% | −2.5—−7.3% | −14*−23741%−35.5% | 27*+261%69.5% | −2.8*—−7.4% | −6.5—−16.8% | 0.1*—0.1% | 7.4*—22.4% | −2.1*—−5.7% | −8.2—−23.7% | −6.2*—−18.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Heron Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- CINVANTI$97 M62%-3.3%
- ZYNRELEF$38 M25%+49%
- APONVIE$12 M7.5%+156%
- SUSTOL$9 M5.5%-40%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Heron Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Craig A. Collard | $3.5 M | $2.0 M | $2.5 M | $6 (peers $120) |
| 2024Craig A. Collard | $3.4 M | $3.5 M | $1.5 M | $7 (peers $91) |
| 2023Craig A. Collard | $10.8 M | $10.9 M | $1.6 M | $8 (peers $92) |
| 2022Barry Quart | $1.1 M | −$2.8 M | $1.4 M | $12 (peers $89) |
| 2021Barry Quart | $5.4 M | −$1.0 M | $1.6 M | $43 (peers $99) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Heron Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 3 · Material agreement 9 · New debt 1 · Unregistered share sale 1 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Material agreementShareholder rights changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreementBylaws or fiscal year changed | 8-K | |
| Material agreementNew debtUnregistered share saleResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2023 | $30 M | Private placement after listing | $10 to $50 million | 7 | equity, options | SEC |
| Jul 2012 | $54 M | Private placement after listing | $50 to $250 million | 21 | equity | SEC |
| Jul 2011 | $24 M | A long-registered or listed company | $10 to $50 million | 22 | equity, options | SEC |
| Oct 2009 | $8 M | A long-registered or listed company | $2 to $10 million | 7 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Heron Therapeutics, Inc.#
$200 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and medicare/medicaid.
- Health Issues4 reports
- Medicare/Medicaid4 reports
Lobbying firms hired in 2025
Farragut Partners LLP $200 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $150 K | — | 3 |
| 2025 | $200 K | — | 4 |
| 2024 | $200 K | — | 4 |
| 2023 | $200 K | — | 4 |
| 2022 | $200 K | — | 4 |
| 2021 | $200 K | — | 4 |
| 2020 | $200 K | — | 4 |
| 2019 | $250 K | — | 5 |
| 2018 | $340 K | — | 7 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Heron Therapeutics, Inc.” and “Farragut Partners LLP on behalf of Heron Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Heron Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2021 for 2 positions, at a median wage of $170 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Pharmaceutical SciencesChemical Engineers | 1 | $140 K |
| Senior Director Business Analysis & InsightsManagement Analysts | 1 | $200 K |
Where: Jersey City, NJ 1 · San Diego, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Heron Therapeutics, Inc.
FDA drug approvals: Heron Therapeutics, Inc.#
4 approved applications held, 1 of them new molecular entities; 0 approvals and 1 new uses in 2024.
| Approved | Drug | Kind |
|---|---|---|
| 2024-01-23 | Zynrelef Kitnew useBupivacaine, Meloxicam · NDA211988 (SUPPL-13) | New drug (NDA) |
| 2022-09-16 | Aponvienew moleculeAprepitant · NDA216457 | New drug (NDA) |
| 2021-12-08 | Zynrelef Kitnew useBupivacaine, Meloxicam · NDA211988 (SUPPL-5) | New drug (NDA) |
| 2021-05-12 | Zynrelef KitBupivacaine, Meloxicam · NDA211988 | New drug (NDA) |
| 2019-10-21 | Cinvantinew useAprepitant · NDA209296 (SUPPL-4) | New drug (NDA) |
| 2019-02-26 | Cinvantinew useAprepitant · NDA209296 (SUPPL-3) | New drug (NDA) |
| 2017-11-09 | CinvantiAprepitant · NDA209296 | New drug (NDA) |
| 2016-08-09 | SustolGranisetron · NDA022445 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (HERON THERAPS INC), so they follow acquisitions
Product recalls by Heron Therapeutics, Inc.#
1 recalls since 2015, 1,790 units in the notices that give a number. Drugs (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Zynrelef (bupivacaine and meloxicam), 400 mg bupivacaine and 12 mg meloxicam single dose application, packaged in a kit, Rx only, Manufactured for Heron Therapeutics, Inc., San Diego, CA, NDC 47426-301-02Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kitDrugsClass III | 1,790 | D-1335-2022 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | 77 | · | · | · | · | · | · | 77 |
| 2008 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| effective | 77 people | LayoffWARN notice | San Diego, California | Notice list |
| 34% of workforce | Restructuring planSEC 8-K | “(the “Company”) approved a reduction in force that is expected to result in the termination of approximately 34% of the Company’s workforce.” | Filing | |
| 35% of workforce | Restructuring planSEC 8-K | “ITEM 2.05 Costs Associated with Exit or Disposal Activities On November 5, 2008, the Company, to better focus the its resources on APF530, announced implementation of a corporate r…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Heron Therapeutics, Inc. compares in Biotechnology
- Market cap$57 M · higher than 28% of 726
- Revenue$155 M · higher than 74% of 647
- Net margin-14.6% · higher than 64% of 408
- Revenue growth7.4% · higher than 51% of 438
- Price / sales0.4× · lower than 98% of 339
- Price / book4.0× · lower than 38% of 534
- FCF yield-48.9% · higher than 24% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Heron Therapeutics, Inc.🇺🇸 | $57 M | — | -14.6% | +7.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Heron Therapeutics, Inc.? Verify and update this profile — free
Show Heron Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.